8-K: XWELL Inc. Reports 14% Revenue Growth in Second Quarter 2024, Driven by Stronger Demand and Cost Reductions

XWELL, Inc. announced a 14% revenue increase in Q2 2024 compared to the same period last year, alongside significant cost reductions and strategic expansions.

Summary

• XWELL, Inc. reported a 14% increase in revenue for the second quarter of 2024, reaching $9.3 million compared to $8.2 million in the same quarter of 2023.
• The revenue growth was primarily driven by increased demand for services and retail products at XpresSpa and Treat locations, which contributed approximately $4.9 million.
• XpresTest, including the biosurveillance partnership and HyperPointe business, generated approximately $3.8 million in revenue.
• Naples Wax Center, acquired in late 2023, contributed approximately $0.5 million to the total revenue.
• The company successfully reduced its cost of sales by approximately 11%, general and administrative expenses by approximately 3%, salaries and benefits by approximately 22%, and total operating expenses by approximately 16% compared to Q2 2023.
• XWELL's operating loss improved significantly, decreasing from approximately $4.7 million in Q2 2023 to approximately $1.9 million in Q2 2024.
• The net loss attributable to XWELL also decreased from approximately $5.7 million in Q2 2023 to approximately $2.0 million in Q2 2024.
• XWELL closed a $1.4 million registered direct offering at a premium to market in August 2024, to be used for working capital and general corporate purposes.
• The company had approximately $5.4 million in cash and cash equivalents, and $13.0 million in marketable securities as of June 30, 2024, with no long-term debt.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and significant cost reductions. However, the company is still operating at a loss, which tempers the overall sentiment. The successful capital raise and strategic expansions are encouraging signs.

Positives

• XWELL experienced a significant increase in revenue, demonstrating strong demand for its services and products.
• The company has made substantial progress in reducing costs across various areas, leading to improved profitability.
• The expansion of XpresSpa locations and services, including the new Philadelphia location and IV-hydration therapy, indicates a strategic focus on growth.
• The potential award of a new CDC biosurveillance contract provides a stable revenue stream.
• The company's strong cash position and lack of long-term debt provide financial stability.
• The registered direct offering at a premium to market demonstrates investor confidence.
• The withdrawal of the lawsuit from CPC Pain & Wellness SPV, LLC is a positive development for the company.

Negatives

• Despite improvements, XWELL still reported an operating loss of approximately $1.9 million and a net loss of approximately $2.0 million for the quarter.
• The company is still reliant on the biosurveillance program for a significant portion of its revenue.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to the biosurveillance program and the expansion of its spa locations.
• The company's ability to secure the new CDC biosurveillance contract is not guaranteed.
• The expansion of Naples Wax Center locations may face challenges in execution and market acceptance.
• The company's reliance on airport locations makes it vulnerable to fluctuations in travel demand.

Future Outlook

XWELL is focused on continuous improvement, expanding its collaboration with the CDC for its traveler-based SARS-CoV-2 Genomic Surveillance program, and opening new locations for both XpresSpa and Naples Wax Center. The company anticipates opening a new XpresSpa location in New York City's Penn Station later this year and expanding Naples Wax Center to approximately 10 locations by early 2025.

Management Comments

• Scott Milford, XWELL's Chief Executive Officer, stated that the company is successfully implementing its strategy to balance its portfolio with growth outside the airport and cost-effectively integrating innovative services and retail products.
• He also noted that the company remains focused on returning to profitability and is pleased with the progress made in reducing costs and operating expenses.

Industry Context

XWELL's focus on wellness solutions in travel hubs aligns with the growing trend of health and wellness services being integrated into travel experiences. The company's expansion into out-of-airport locations with Naples Wax Center reflects a broader strategy to diversify its revenue streams and tap into the growing demand for aesthetic services. The biosurveillance program is a unique offering that positions XWELL as a key player in public health monitoring within the travel industry.

Comparison to Industry Standards

• XWELL's 14% revenue growth in Q2 2024 is a positive sign, but it is important to compare this to other companies in the wellness and airport retail sectors.
• Companies like Massage Envy and other spa chains may serve as benchmarks for XpresSpa's performance, though direct comparisons are difficult due to XWELL's unique airport focus.
• The cost reduction efforts are significant, and it would be beneficial to compare these to industry averages for similar businesses.
• The biosurveillance program is a unique offering, and there are no direct industry standards for comparison, but the value of the contract should be compared to other government contracts in the health sector.
• The expansion of Naples Wax Center should be compared to other aesthetic service providers in the Florida market, such as European Wax Center and local boutiques.

Legal Proceedings

• The company announced the withdrawal of a previously filed lawsuit from CPC Pain & Wellness SPV, LLC.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, reduced losses, and strategic growth initiatives.
• Employees may see improved job security and potential for growth as the company expands.
• Customers will have access to a wider range of wellness services and products.
• Suppliers may see increased demand for their products and services.
• Creditors will be reassured by the company's improved financial performance and strong cash position.

Next Steps

• XWELL will continue to focus on reducing its cost structure and returning to profitability.
• The company will pursue the new three-year biosurveillance program RFP from the CDC.
• XWELL plans to open a new XpresSpa location in New York City's Penn Station later this year.
• The company intends to expand Naples Wax Center to approximately 10 locations by early 2025.
• XWELL will continue to integrate innovative services and retail products into its offerings.

Key Dates

Keywords

XWELL, XpresSpa, Naples Wax Center, XpresCheck, HyperPointe, Biosurveillance, Wellness, Airport Retail, Revenue Growth, Cost Reduction, Financial Results, CDC, IV Hydration, Direct Offering